To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT00827996 | Completed Phase 2 DMC

• 1 other identifier: HIDRI2007
• Study Type: interventional
• Target: 10
• Locations: 0 countries
• Sites: N/A

Brief Summary

The trial is a 12-week phase 2 study. Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12 in subjects with moderate to severe hidradenitis suppurativa.

Conditions

Hidradenitis Suppurativa

Keywords

Apocrine glands; abcesses

Outcome Measures

Primary Outcomes (1)

• To assess the efficacy and safety of adalimumab in subjects with moderate to severe hidradenitis suppurativa. Efficacy will be evaluated using the included Hidradenitis Suppurativa Severity Index (HSSI).

  13 weeks

Secondary Outcomes (2)

• To evaluate the role of TNF alpha in the pathogenesis of hidradenitis suppurativa.

  13 weeks

• To evaluate the ability of adalimumab to maintain suppression of the disease.

  13 weeks

Interventions

adalimumab DRUG

Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects with moderate to severe HS as defined by a HSSI \> 8 AND at least ONE of the following:
• HS \>1 year duration with multiple ER or doctors visits related to HS
• Intralesional kenalog injection \>5/year, however none within 2 weeks of entry
• Failed systemic retinoids, but not within 3 months of entry
• Failed at least one prior course of antibiotic therapy, which must not have been administered within 2 weeks of entry to the study (excluding the recommended antibiotic regimen given for evidence of active infection immediately before enrollment)
• History of surgery (reconstructive), but not within 3 months of entry

You may not qualify if:

• Women who are pregnant, nursing, or planning pregnancy within 6 months after the last injection (this includes father's who plan on fathering a child within 6 months after their last injection).
• Use of other systemic anti-inflammatory medication except NSAIDs and low dose systemic steroids (equal or less than 10 mg daily prednisolone or equivalent).
• If found to have an active infection, patients must have completed topical or oral antibiotic therapy at least 7 days before first injection.
• Have a known history of serious infections (e.g., hepatitis, pneumonia or pyelonephritis) in the previous 3 months.
• Have or have had an opportunistic infection (e.g., herpes zoster \[shingles\], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening.
• Have a history of lymphoproliferative disease, including lymphoma or signs suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location (e.g., nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic area), or splenomegaly.
• Have a concomitant diagnosis or history of congestive heart failure.
• Have a history of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis, prior to screening.

Sponsors & Collaborators

• Florida Academic Dermatology Centers: lead
• Abbott: collaborator

MeSH Terms

Conditions

Hidradenitis Suppurativa

Interventions

Adalimumab

Condition Hierarchy (Ancestors)

Skin Diseases, Bacterial; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Skin Diseases, Infectious; Suppuration; Skin Diseases; Skin and Connective Tissue Diseases; Hidradenitis; Sweat Gland Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Officials

• Francisco A Kerdel, M.D

  Florida Academic Dermatology Centers

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: January 21, 2009
• First Posted: January 23, 2009
• Study Start: February 1, 2007
• Primary Completion: November 1, 2007
• Study Completion: August 1, 2008
• Last Updated: January 23, 2009

Record last verified: 2009-01